ロード中...
PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development
Prostate cancer is globally the second most commonly diagnosed cancer type in men. Recent studies suggest that mutations in DNA repair genes are associated with aggressive forms of prostate cancer and castration resistance. Prostate cancer with DNA repair defects may be vulnerable to therapeutic tar...
保存先:
| 出版年: | Genes (Basel) |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6723995/ https://ncbi.nlm.nih.gov/pubmed/31357527 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/genes10080565 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|